Transvenous Defibrillation and Radiofrequency Ablation [antikvár]

Preface The development of the cardiac pacemaker from a historical first implant to a no longer rare medical therapy using a technically acceptable device took about a decade. In a similar fashion, about 10 years passed between Dr. Mirowski's first human application of the automatic implantable defibrillator and the rapidly growing clinical acceptance of multi-programmable implantable cardioverter-defibrillators (ICDs) supported by indication guidelines from professional societies. In 1991, Medtronic sponsored a symposium in Interlaken, Switzerland, in which indications, implant and follow-up techniques, clinical results of pacing and low energy cardioversion for termination of ventricular tachycardia, and other medical aspects of implantable defibrillators were presented and discussed by physicians who had participated in the clinical evaluation of new third generation ICDs. Most experience at that time had been obtained with epicardial defibrillation leads. The proceedings of this meeting were published in 1992 in Volume 5 of the Bakken Research Center Series entitled Practical Aspects of Staged Therapy Defibrillators.* At the second Interlaken Symposium, New Waves in Arrhythmia Therapies (1993), the program included electrophysiological aspects of atrial and ventricular fibrillation and defibrillation, results achieved with transvenous defibrillation lead systems, new indications for ICDs, and principles and practical aspects of myocardial ablation. The authors of this book have based their contributions on their presentations at this Symposium. Although developments in the field of implantable defibrillators, with a clear trend towards pectoral implantation and extended memory functions, and in myocardial ablation, such as "LJ Kappenberger, FW Lindemans: Practical Aspects of Staged Therapy Defibrillators. Mount Kisco, NY, Futura Publishing Co, 1992.